BRPI0922849A2 - vacina para a prevenção de recorrência de câncer de mama - Google Patents

vacina para a prevenção de recorrência de câncer de mama

Info

Publication number: BRPI0922849A2
Authority: BR; Brazil
Prior art keywords: vaccine; prevention; breast cancer; cancer recurrence; recurrence
Prior art date: 2008-12-10

Application number

BRPI0922849A

Other languages

English (en)

Inventor

Peoples George

Ponniah Sathibalan

Original Assignee

Henry M Jackson Found Advancement Military Medicine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-10

Filing date

2009-12-09

Publication date

2017-05-30

2009-12-09 Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc

2017-05-30 Publication of BRPI0922849A2 publication Critical patent/BRPI0922849A2/pt

2023-01-24 Publication of BRPI0922849B1 publication Critical patent/BRPI0922849B1/pt

Links

206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Oncology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0922849-7A 2008-12-10 2009-12-09 Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf BRPI0922849B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12122008P	2008-12-10	2008-12-10
US61/121,220		2008-12-10
PCT/US2009/067264 WO2010068647A1 (en)	2008-12-10	2009-12-09	Vaccine for the prevention of breast cancer recurrence

Publications (2)

Publication Number	Publication Date
BRPI0922849A2 true BRPI0922849A2 (pt)	2017-05-30
BRPI0922849B1 BRPI0922849B1 (pt)	2023-01-24

Family

ID=42243054

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0922849-7A BRPI0922849B1 (pt)	2008-12-10	2009-12-09	Composição de vacina com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
BR122021010546-4A BR122021010546B1 (pt)	2008-12-10	2009-12-09	Uso de uma composição com uma quantidade eficaz de um peptídeo gp2 e de gm-csf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122021010546-4A BR122021010546B1 (pt)	2008-12-10	2009-12-09	Uso de uma composição com uma quantidade eficaz de um peptídeo gp2 e de gm-csf

Country Status (11)

Country	Link
US (2)	US9114099B2 (pt)
EP (2)	EP3238740A1 (pt)
JP (2)	JP6220111B2 (pt)
KR (2)	KR20110106338A (pt)
CN (2)	CN102245197A (pt)
AU (1)	AU2009324707B2 (pt)
BR (2)	BRPI0922849B1 (pt)
CA (1)	CA2744035C (pt)
ES (1)	ES2639577T3 (pt)
HK (1)	HK1223028A1 (pt)
WO (1)	WO2010068647A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8945573B2 (en) *	2005-09-08	2015-02-03	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Targeted identification of immunogenic peptides
EP3238740A1 (en)	2008-12-10	2017-11-01	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Vaccine for the prevention of breast cancer recurrence
BR112013033974A2 (pt)	2011-07-01	2017-02-14	Biosceptre Int Ltd	terapia de combinação
CN102532268B (zh) *	2012-03-12	2013-12-18	胡海波	具有抗乳腺癌活性的寡肽及其应用
CA2899263A1 (en) *	2013-01-29	2014-08-07	Molecular Health Ag	Systems and methods for clinical decision support
US20160258951A1 (en) *	2013-10-28	2016-09-08	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Methods of monitoring immune responses
CN103923176B (zh) *	2014-04-25	2015-12-30	青岛市海慈医疗集团	具有抗乳腺癌活性的寡肽及其应用
CN107141351A (zh) *	2017-05-15	2017-09-08	广州领晟医疗科技有限公司	一种e75肽的液相合成方法
KR20240159834A (ko) *	2022-03-08	2024-11-06	그리니치 라이프사이언스 인코포레이티드	대상체에서 생존을 증가시키기 위해 억제된 면역 상태를 역전시키기 위한 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4744984A (en)	1985-10-08	1988-05-17	Vetrepharm Research, Inc.	Antiviral immunotherapeutic agent and preparation thereof
US5801005A (en)	1993-03-17	1998-09-01	University Of Washington	Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5550214A (en) *	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US6514942B1 (en)	1995-03-14	2003-02-04	The Board Of Regents, The University Of Texas System	Methods and compositions for stimulating T-lymphocytes
US5891432A (en) *	1997-07-29	1999-04-06	The Immune Response Corporation	Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6969609B1 (en) *	1998-12-09	2005-11-29	The United States Of America As Represented By The Department Of Health And Human Serivces	Recombinant vector expressing multiple costimulatory molecules and uses thereof
US20040121946A9 (en)	2000-12-11	2004-06-24	John Fikes	Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
WO2003055439A2 (en)	2001-07-18	2003-07-10	The Regents Of The University Of California	Her2/neu target antigen and use of same to stimulate an immune response
AU2003230603A1 (en)	2002-03-08	2003-09-22	Board Of Regents, The University Of Texas System	Controlled modulation of amino acid side chain length of peptide antigens
CN1288166C (zh) *	2004-07-14	2006-12-06	吉林圣元科技有限责任公司	修饰的肿瘤抗原肽及其应用
US8945573B2 (en) *	2005-09-08	2015-02-03	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Targeted identification of immunogenic peptides
CA2687368C (en)	2007-06-01	2018-10-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Vaccine for the prevention of breast cancer relapse
EP3238740A1 (en)	2008-12-10	2017-11-01	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Vaccine for the prevention of breast cancer recurrence

2009
- 2009-12-09 EP EP17174362.8A patent/EP3238740A1/en not_active Withdrawn
- 2009-12-09 CN CN2009801494947A patent/CN102245197A/zh active Pending
- 2009-12-09 CA CA2744035A patent/CA2744035C/en active Active
- 2009-12-09 BR BRPI0922849-7A patent/BRPI0922849B1/pt active IP Right Grant
- 2009-12-09 EP EP09832462.7A patent/EP2355843B8/en active Active
- 2009-12-09 KR KR1020117015494A patent/KR20110106338A/ko not_active Ceased
- 2009-12-09 CN CN201510881138.1A patent/CN105435218A/zh active Pending
- 2009-12-09 KR KR1020177022727A patent/KR20170097234A/ko not_active Withdrawn
- 2009-12-09 BR BR122021010546-4A patent/BR122021010546B1/pt active IP Right Grant
- 2009-12-09 WO PCT/US2009/067264 patent/WO2010068647A1/en not_active Ceased
- 2009-12-09 ES ES09832462.7T patent/ES2639577T3/es active Active
- 2009-12-09 JP JP2011540853A patent/JP6220111B2/ja active Active
- 2009-12-09 US US13/133,487 patent/US9114099B2/en active Active
- 2009-12-09 AU AU2009324707A patent/AU2009324707B2/en active Active
2015
- 2015-07-30 US US14/813,927 patent/US9737596B2/en active Active
2016
- 2016-09-27 HK HK16111312.0A patent/HK1223028A1/zh unknown
2017
- 2017-07-11 JP JP2017135106A patent/JP6387156B2/ja active Active

Also Published As

Publication number	Publication date
CA2744035C (en)	2018-07-24
EP2355843B8 (en)	2017-08-02
CN105435218A (zh)	2016-03-30
US20160022790A1 (en)	2016-01-28
EP2355843B1 (en)	2017-06-07
ES2639577T3 (es)	2017-10-27
CA2744035A1 (en)	2010-06-17
KR20110106338A (ko)	2011-09-28
BR122021010546B1 (pt)	2022-08-02
HK1223028A1 (zh)	2017-07-21
US20110256164A1 (en)	2011-10-20
EP2355843A1 (en)	2011-08-17
US9114099B2 (en)	2015-08-25
AU2009324707A1 (en)	2010-06-17
EP3238740A1 (en)	2017-11-01
KR20170097234A (ko)	2017-08-25
CN102245197A (zh)	2011-11-16
EP2355843A4 (en)	2013-04-17
JP2012511578A (ja)	2012-05-24
WO2010068647A1 (en)	2010-06-17
JP6387156B2 (ja)	2018-09-05
JP2018008960A (ja)	2018-01-18
BRPI0922849B1 (pt)	2023-01-24
US9737596B2 (en)	2017-08-22
JP6220111B2 (ja)	2017-10-25
AU2009324707B2 (en)	2015-04-30

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-09-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-02-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2022-06-07	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-10-25	B25G	Requested change of headquarter approved	Owner name: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US)
2023-01-24	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
HUS2300018I1 (hu)	2023-05-28	Rákellenes hatású kinoli-8-szulfonamid-származékok
PT2162149E (pt)	2014-02-12	Vacina para a prevenção da recaída do cancro da mama
PT2456889E (pt)	2014-11-21	Marcadores para o cancro do endométrio
CY2023015I1 (el)	2024-02-16	Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
BRPI1006438A2 (pt)	2016-09-27	terapia adjuvante de cancer
PT2829881T (pt)	2017-11-29	Diagnóstico para cancro colo-rectal
BR112012005594A2 (pt)	2015-09-08	tratamento de câncer
BR112014002200A2 (pt)	2017-03-07	tratamento de câncer de mama
EP2382331A4 (en)	2013-01-16	KREBSBIOMARKER
EP2625292A4 (en)	2014-03-19	KREBSBIOMARKER
GB201016139D0 (en)	2010-11-10	Cancer phosholipidome
BRPI1014998A2 (pt)	2016-04-26	peptídio auxiliador de antígeno de câncer
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI1008664A2 (pt)	2016-03-08	comprimidos para a terapia de combinação
BRPI1007495A2 (pt)	2016-09-06	detonador
EP2283862A4 (en)	2012-09-26	ANTITUMOR AGENT
EP2355843B8 (en)	2017-08-02	Vaccine for the prevention of breast cancer recurrence
GB201003293D0 (en)	2010-04-14	Cancer vaccine
GB0918722D0 (en)	2009-12-09	Anti cancer agent
BRPI1009435A2 (pt)	2016-03-01	tratamento para câncer no pâncreas
EP2585115A4 (en)	2014-12-17	Cancer therapy
EP2565192A4 (en)	2013-10-16	CANCER AGENT
EP2501845A4 (en)	2013-04-24	KREBSBIOMARKER
GB0910751D0 (en)	2009-08-05	Prostate cancer vaccine
EP2502627A4 (en)	2013-07-31	ANTI CANCER AGENTS